The next generation biopharmaceuticals
Henrik Krook has a broad Life Science perspective and a solid network gained from over 15 years of leader roles in settings varying from University Hospital to Big Pharma and Biotech. He has direct experience from employments as General Manager and various senior roles within business development, clinical trial management, commercialization and strategy formulation at Roche, Novartis, Medivir and Alexion. Henrik holds a Master of Science in Pharmacy and a PhD in Immunology from Uppsala University as well as an Executive MBA from the Stockholm School of Economics. Since 2017 Henrik acts as board member, consultant and advisor to Biotech companies and Life Science Projects.
Peter Lind has expertise in the early phases of the drug discovery and development process, including the path from disease, unmet medical need, as well as target assessment and validation, to development program launch. Peter is the founder and owner of Tilia Bioconsulting AB and a Senior Advisor to Affibody AB. Peter holds a PhD in Biochemistry from Uppsala University, and has more than 30 years of experience in the Biotechnology and Pharmaceutical industry. Peter has previously been assigned as project leader at KabiGen AB in the early discovery, and development of the first engineered form of coagulation factor eight for the treatment of haemophilia A (ReFacto™). In addition, Peter helped establishing discovery research in metabolic diseases at Pharmacia & Upjohn, and has been Principal Scientist, active in the area of Autoimmunity and Inflammation, at Biovitrum AB (now SOBI).
Tomas Moks is an expert in Process Development and Industrial Biopharmaceutical manufacturing. Tomas is a co-founder of and a Senior CMC Advisor to Affibody AB. Tomas holds a Ph.D. in Biochemistry and Biotechnology with >30 years in senior positions in the Biopharmaceutical Industry. Previous assignments include Global Head of BioProcess Development in Pharmacia (now Pfizer), member of Pharmacia's European Global Supply management and Head of Licensing and Contract manufacturing in Biovitrum (now SOBI). Since 2010 Tomas acts as a Senior CMC Advisor to Biopharma companies as well as advisor at Wallenberg Center for Protein Research (WPCR) at KTH.
Affibodys latest Press releases
Affibody in short
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Upcoming reports Financial calendar
- Interim Report Q2 (August 23, 2018)